Bicara Therapeutics Inc. BCAX
Set alert
At close · Oct 30
After hours · Oct 30, 7:42 PM ET
- YTD
- -45.75%
- 1 year
- -44.53%
- Open
- 9.38
- Prev close
- 9.73
- Mkt cap
- 604.16M
- Vol
- 4.20M
- Avg vol
- 973.12K
- EPS
- -3.08
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.36
- High
- 9.38
- Forward P/E
- -4.96
- Beta
- -0.69
- Short ratio
- 16.85
- Inst. own
- 102.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 20.82
- 200-d avg
- 21.33
- 1y target
- 35.67
5D chart
Signals (112)
| Name | Time | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 3:50 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:40 PM | 1 day ago |
| SMA: Bearish | Oct 30, 3:25 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 3:25 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:20 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:10 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 2:05 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:00 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 1:40 PM | 1 day ago |
| SMA: Bearish | Oct 30, 1:15 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 11:45 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:30 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:55 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:50 AM | 2 days ago |
| RSI: Oversold | Oct 30, 10:20 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 3:35 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:15 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:30 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:20 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:15 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:15 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:45 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 1:40 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:35 PM | 2 days ago |
| RSI: Overbought | Oct 29, 1:15 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 12:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 11:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:00 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:55 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:05 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:05 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 10:05 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 9:45 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:35 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:45 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:15 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:25 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:20 AM | 4 days ago |
| RSI: Oversold | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:55 PM | 4 days ago |
| RSI: Overbought | Oct 27, 3:20 PM | 4 days ago |
| RSI: Overbought | Oct 27, 3:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:15 PM | 5 days ago |
| RSI: Overbought | Oct 27, 10:55 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:25 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:20 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:00 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| RSI: Overbought | Oct 26, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:25 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:10 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:25 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:00 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:00 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:35 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:10 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:55 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:50 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:45 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:20 AM | 6 days ago |
News
-
1 day ago benzinga.com
Goldman Sachs Downgrades Bicara Therapeutics to Sell, Lowers Price Target to $8
Goldman Sachs analyst Richard Law downgrades Bicara Therapeutics (NASDAQ:BCAX) from Neutral to Sell and lowers the price target from $20 to $8.
-
3 days ago benzinga.com
Wedbush Maintains Outperform on Bicara Therapeutics, Lowers Price Target to $24
Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and lowers the price target from $33 to $24.
3 days ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…
1 week ago defenseworld.net
Bicara Therapeutics (NASDAQ:BCAX) Given Buy Rating at BTIG Research
Bicara Therapeutics (NASDAQ: BCAX - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at BTIG Research in a research report issued on Monday, Benzinga reports. They…
-
1 week ago benzinga.com
BTIG Reiterates Buy on Bicara Therapeutics, Maintains $39 Price Target
BTIG analyst Jeet Mukherjee reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Buy and maintains $39 price target.
3 weeks ago globenewswire.com
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients…
1 month ago globenewswire.com
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients…
-
2 months ago benzinga.com
BMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target of $35
BMO Capital analyst David Lebowitz initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Outperform rating and announces Price Target of $35.
2 months ago globenewswire.com
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients…
2 months ago defenseworld.net
Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAX
Dimensional Fund Advisors LP grew its holdings in Bicara Therapeutics Inc. (NASDAQ: BCAX) by 166.9% during the undefined quarter, according to its most recent Form 13F filing with the Securities and…
-
2 months ago benzinga.com
Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20
Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $18 to $20.
-
2 months ago benzinga.com
Wedbush Maintains Outperform on Bicara Therapeutics, Raises Price Target to $33
Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and raises the price target from $30 to $33.
-
2 months ago benzinga.com
Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $39
Morgan Stanley analyst Judah Frommer maintains Bicara Therapeutics (NASDAQ:BCAX) with a Overweight and raises the price target from $37 to $39.
2 months ago seekingalpha.com
Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds
Bicara Therapeutics (BCAX) is upgraded to 'Buy' on favorable early clinical signals for ficerafusp alfa in head and neck cancer. BCAX's phase 1 data show promising median overall survival, but…
-
2 months ago benzinga.com
Mizuho Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20
Mizuho analyst Joseph Catanzaro maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $18 to $20.
2 months ago benzinga.com
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
Bicara Therapeutics Inc (NASDAQ:BCAX) reported a narrower-than-expected loss for the second quarter on Tuesday.
2 months ago benzinga.com
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
Bicara Therapeutics (BCAX) reported a narrower-than-expected loss in Q2. Analysts raised price targets, but shares dipped 14.3% to $23.76. #BCAX #earnings
-
2 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on Bicara Therapeutics, Raises Price Target to $23
Wells Fargo analyst Eva Fortea Verdejo maintains Bicara Therapeutics (NASDAQ:BCAX) with a Equal-Weight and raises the price target from $16 to $23.
-
2 months ago benzinga.com
BTIG Maintains Buy on Bicara Therapeutics, Raises Price Target to $39
BTIG analyst Jeet Mukherjee maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and raises the price target from $28 to $39.
2 months ago seekingalpha.com
Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript
Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Bicara Therapeutics Q2 Earnings Call Highlights
Bicara Therapeutics NASDAQ: BCAX used its second-quarter 2026 earnings call to outline leadership changes, progress in its pivotal head and neck cancer program and plans to expand development of…
-
2 months ago benzinga.com
Bicara Therapeutics Q2 EPS $(0.82) Beats $(0.84) Estimate
Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.82) per share which beat the analyst consensus estimate of $(0.84) by 2.38 percent. This is a 64 percent decrease over losses of…
2 months ago globenewswire.com
Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 91.1% to $6.04 during Friday's after-market session. The company's market cap stands at $2.2 million. BGM Group (NASDAQ:BGM) stock…
3 months ago globenewswire.com
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
BOSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients…
4 months ago globenewswire.com
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients…
4 months ago fool.com
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
CEO Claire Mazumdar sold 15,000 shares for a transaction value of approximately ~$301,000, based on a weighted average price of around $20.04 per share on May 18, 2026. This represented 3.98% of…
5 months ago seekingalpha.com
Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript
Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript
5 months ago marketbeat.com
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
Bicara Therapeutics NASDAQ: BCAX said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by…
-
5 months ago benzinga.com
Bicara Therapeutics' Ficerafusp Alfa Plus Pembrolizumab Shows 31% Estimated 3-Year Overall Survival And Durable Responses In First-Line HPV-Negative Head And Neck Cancer Phase 1b Study
At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a
5 months ago globenewswire.com
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a…
5 months ago fool.com
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions.
5 months ago marketbeat.com
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data
Bicara Therapeutics NASDAQ: BCAX said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development…
5 months ago seekingalpha.com
Bicara Therapeutics Inc. (BCAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Bicara Therapeutics Inc. (BCAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
5 months ago globenewswire.com
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients…
-
5 months ago benzinga.com
Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $18
Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $16 to $18.
-
5 months ago benzinga.com
Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $37
Morgan Stanley analyst Judah Frommer maintains Bicara Therapeutics (NASDAQ:BCAX) with a Overweight and raises the price target from $36 to $37.
-
5 months ago benzinga.com
Guggenheim Initiates Coverage On Bicara Therapeutics with Buy Rating, Announces Price Target of $42
Guggenheim analyst Brad Canino initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Buy rating and announces Price Target of $42.
-
5 months ago benzinga.com
Bicara Therapeutics Q1 EPS $(0.93) Misses $(0.68) Estimate
Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.68) by 36.76 percent. This is a 36.76 percent decrease over losses…
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
7 months ago benzinga.com
Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $16
Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $14 to $16.
-
7 months ago benzinga.com
Wedbush Reiterates Outperform on Bicara Therapeutics, Maintains $30 Price Target
Wedbush analyst David Nierengarten reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and maintains $30 price target.
-
7 months ago benzinga.com
Wells Fargo Maintains Equal-Weight on Bicara Therapeutics, Raises Price Target to $16
Wells Fargo analyst Eva Fortea Verdejo maintains Bicara Therapeutics (NASDAQ:BCAX) with a Equal-Weight and raises the price target from $11 to $16.
7 months ago benzinga.com
Bicara Therapeutics To Rally Around 121%? Here Are 10 Top Analyst Forecasts For Tuesday
Top analysts changed outlook on top names. See all changes on analyst ratings page. BTIG & HCW cut price targets, Needham & BMO raised, Baird bcut.
-
7 months ago benzinga.com
Citizens Reiterates Market Outperform on Bicara Therapeutics, Maintains $31 Price Target
Citizens analyst Reni J. Benjamin reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Market Outperform and maintains $31 price target.
-
7 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Bicara Therapeutics, Raises Price Target to $42
HC Wainwright & Co. analyst Robert Burns maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and raises the price target from $40 to $42.
-
7 months ago benzinga.com
Bicara Therapeutics Q4 EPS $(0.68), Inline
Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.68) per share which met the analyst consensus estimate. This is a 74.36 percent decrease over losses of $(0.39) per share from the…
-
7 months ago benzinga.com
Earnings Scheduled For March 30, 2026
Earnings Scheduled For March 30, 2026
7 months ago benzinga.com
Bicara Therapeutics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Bicara Therapeutics Inc (BCAX) to release Q4 earnings on March 30. Expected loss of 65 cents/share. Analysts have mixed ratings and price targets.